Rectal cancer
Conditions
Interventions
None listed
Sponsors
Nippon Medical School
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: A) Histologically confirmed stage I-III rectal carcinoma B) Without metastasis and/or invasion of adjacent organs C) Laparoscopic or robotic surgery performed D) Curative surgery performed E) Using anti-adhesion barriers (Seprafilm, Interceed, and Adspray) during rectal cancersurgery F) Patient with age between 20 and 80 years G) Any intervals between initial surgery (rectal cancer surgery) and ileostomy reversal H) Patient with an Eastern Cooperative Oncology GroupPerformance Status of 0 or 1 I) Exhibiting sufficient organ function within 1 month prior to enrollment in the study with the following parameters considered: -White blood cell count: 3,000/mm3 or higher -Platelet count: 75,000/mm3 or higher -Hemoglobin: 8.0 g/dl or higher -Serum AST and ALT: 2.5 times or less than the upper limit of the institutional reference value -Serum total bilirubin: less than 1.5 mg/dl -Serum creatinine: 1.5 mg/dl or less
Exclusion criteria
Exclusion criteria: A) Contraindications for Seprafilm use B) History of previous abdominal surgery, except for appendectomy, laparoscopic cholecystectomy, and cesarean section performed >5 years prior C) Cases of small bowel obstruction prior to ileostomy reversal D) The treating physician did not feel that the use of Seprafilm was appropriate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of postoperative small bowel obstruction 2 years after ileostomy reversal | — |
Countries
Japan
Contacts
Public ContactAkihisa Matsuda
Nippon Medical School Hospital Department of Gastrointestinal Hepato-Biliary-Pancreatic Surgery
Outcome results
None listed